Advent Life Sciences
Capital Type
Venture Capital
Investment Size
Undisclosed / varies by deal
Geographic Scope
Europe, Global
Return Model
Dilutive
Stage Focus
Early to Clinical
Modality Focus
Therapeutics, Anti-infectives
Overview
European venture investor focused on innovative life science companies across therapeutics and enabling technologies.
Portfolio and Signals
Notable anti-infective signal through F2G and through team depth in antibiotic development, making Advent more relevant to AMR than many generalist biotech funds.
Access and Engagement
Best approached through European biotech networks, strong data packages, and specialist investor introductions.
Notable AMR Examples / Programs
F2G and specialist European biotech investing
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
